Health Trials

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

ConditionsMetastatic Castration-resistant Prostate Cancer, MCRPCCancer
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorZhengguo Chen

About this trial

161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.

Eligibility criteria

Qualifiers

The participant voluntarily signs the informed consent form and is able to complete the trial according to the protocol requirements.

Male, aged 18 years or older.

Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) as per PCWG3 criteria.

Positive results on 68Ga-NYM032 positron emission tomography (PET)/computed tomography (CT) scan.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • 30 mCi NYMO32
  • 50 mCi NYMO32
  • 80 mCi NYMO32
  • 130 mCi NYMO32
  • 200 mCi NYMO32

Treatment groups

15 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Zhengguo Chen

Lead sponsor

Mianyang Central Hospital

Sponsor institution

Source ClinicalTrials.gov